Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Mutation enrichment in targeted panels flags immunotherapy-responsive POLE-driven hypermutated microsatellite-stable colorectal cancers.

NPJ precision oncology·2026
Same author

Seminal vesicle injury during radical prostatectomy does not affect the oncological outcome of prostate cancer patients.

Prostate international·2026
Same author

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

NPJ precision oncology·2026
Same author

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Seminars in cancer biology·2026

Related Experiment Video

Updated: Dec 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes.

Mark Kriegsmann1,2, Christiane Zgorzelski1, Rita Casadonte3

  • 1Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany.

Cancers
|September 24, 2020
PubMed
Summary

Mass spectrometry imaging (MSI) accurately subtypes non-small cell lung cancer (NSCLC) into adenocarcinoma (ADC) and squamous cell carcinoma (SqCC). This largest-to-date MSI NSCLC cohort study validates its high diagnostic performance, comparable to immunohistochemistry (IHC).

Keywords:
NSCLClung cancermass spectrometrymass spectrometry imaging

More Related Videos

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
05:00

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample

Published on: November 21, 2023

2.5K
Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.7K

Related Experiment Videos

Last Updated: Dec 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
05:00

Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample

Published on: November 21, 2023

2.5K
Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.7K

Area of Science:

  • Oncology
  • Analytical Chemistry
  • Biomarker Discovery

Background:

  • Accurate subtyping of non-small cell lung cancer (NSCLC) is crucial for effective therapy stratification.
  • Mass spectrometry imaging (MSI) offers potential for label-free molecular subtyping of cancer tissues.
  • Previous MSI studies on NSCLC have been limited by smaller patient cohorts.

Purpose of the Study:

  • To analyze the largest non-small cell lung cancer (NSCLC) cohort using mass spectrometry imaging (MSI) to date.
  • To evaluate and compare different classification algorithms for NSCLC subtyping.
  • To validate MSI findings against established methods like immunohistochemistry (IHC).

Main Methods:

  • Analysis of tissue microarrays (TMAs) from 939 NSCLC patients (499 adenocarcinoma, 440 squamous cell carcinoma).
  • Application of classification algorithms: linear discriminant analysis, support vector machine, and random forest (RF).
  • Identification and validation of key molecular species (m/z values) using on-tissue tandem mass spectrometry and IHC.

Main Results:

  • Random forest (RF) demonstrated the highest classification accuracy for NSCLC subtypes.
  • Classification accuracy was optimal using a limited set of the most relevant m/z species.
  • MSI achieved high sensitivity (92.9%) and specificity (89.3%) in the validation cohort, comparable to IHC.
  • Cytokeratin 5 was identified as a key protein marker distinguishing NSCLC subtypes.

Conclusions:

  • MSI is a powerful tool for accurate and reproducible subtyping of non-small cell lung cancer (NSCLC) into adenocarcinoma (ADC) and squamous cell carcinoma (SqCC).
  • A small panel of specific m/z species is sufficient for high-accuracy classification.
  • MSI offers a promising complementary or alternative diagnostic approach to IHC for NSCLC subtyping.